- Home
- ANVS vs MAIA Comparison
ANVS vs MAIA Comparison
Compare ANVS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- MAIA
- Stock Information
- Founded
- ANVS 2008
- MAIA 2018
- Country
- ANVS United States
- MAIA United States
- Employees
- ANVS N/A
- MAIA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- MAIA Health Care
- Exchange
- ANVS Nasdaq
- MAIA Nasdaq
- Market Cap
- ANVS 110.4M
- MAIA 62.4M
- IPO Year
- ANVS 2020
- MAIA 2022
- Fundamental
- Price
- ANVS $9.57
- MAIA $2.82
- Analyst Decision
- ANVS Strong Buy
- MAIA
- Analyst Count
- ANVS 6
- MAIA 0
- Target Price
- ANVS $29.67
- MAIA N/A
- AVG Volume (30 Days)
- ANVS 341.4K
- MAIA 60.0K
- Earning Date
- ANVS 11-06-2024
- MAIA 11-05-2024
- Dividend Yield
- ANVS N/A
- MAIA N/A
- EPS Growth
- ANVS N/A
- MAIA N/A
- EPS
- ANVS N/A
- MAIA N/A
- Revenue
- ANVS N/A
- MAIA N/A
- Revenue This Year
- ANVS N/A
- MAIA N/A
- Revenue Next Year
- ANVS N/A
- MAIA N/A
- P/E Ratio
- ANVS N/A
- MAIA N/A
- Revenue Growth
- ANVS N/A
- MAIA N/A
- 52 Week Low
- ANVS $4.53
- MAIA $0.82
- 52 Week High
- ANVS $22.49
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- ANVS 58.70
- MAIA 50.98
- Support Level
- ANVS $9.00
- MAIA $2.36
- Resistance Level
- ANVS $10.54
- MAIA $2.72
- Average True Range (ATR)
- ANVS 0.81
- MAIA 0.22
- MACD
- ANVS 0.12
- MAIA 0.02
- Stochastic Oscillator
- ANVS 74.57
- MAIA 72.28
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.